Presentation
- Home
- Education Events
- Presentation
- The estimated healthcare spend to identify 1 hereditary cancer syndrome patient with a deep intronic pathogenic variant by rna sequencing is nearly 500x more costly than identifying 1 patient with multi-gene panel dna testing
The estimated healthcare spend to identify 1 hereditary cancer syndrome patient with a deep intronic pathogenic variant by rna sequencing is nearly 500x more costly than identifying 1 patient with multi-gene panel dna testing
01 Nov 2023